Boehringer Ingelheim pins hopes on Pradaxa to boost sales
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is targeting its anticoagulant Pradaxa (dabigatran etexilate) to drive future sales as Flomax (tamsulosin hydrochloride) and Mirapex (pramipexole dihydrochloride) face patent expiries in 2010.